Home > Back to Publisher > Report Information

The 2010-2015 World Outlook for Monoclonal Antibody (MAb)-Based Products

Icon Group International, Inc.
July 7, 2009
196 Pages - SKU: ICN2525737

Abstract Table of Contents Search inside this report Related Reports

Countries covered: Global

This econometric study covers the world outlook for Monoclonal Antibody (MAb)-based products across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved."

Additional Information

This econometric study covers the world outlook for Monoclonal Antibody (MAb)-based products across more than 200 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

1 INTRODUCTION: 1.1 Overview; 1.2 What is Latent Demand and the P.I.E.?; 1.3 The Methodology
2 SUMMARY OF FINDINGS: 2.1 The Worldwide Market Potential
3 ASIA & OCEANA: 3.1 Executive Summary; 3.2 American Samoa; 3.3 Australia; 3.4 Bangladesh; 3.5 Bhutan; 3.6 Brunei; 3.7 Burma; 3.8 Cambodia; 3.9 China; 3.10 Christmas Island; 3.11 Cook Islands; 3.12 Fiji; 3.13 French Polynesia; 3.14 Guam; 3.15 Hong Kong; 3.16 India; 3.17 Indonesia; 3.18 Japan; 3.19 Kiribati; 3.20 Laos; 3.21 Macau; 3.22 Malaysia; 3.23 Maldives; 3.24 Marshall Islands; 3.25 Micronesia Federation; 3.26 Mongolia; 3.27 Nauru; 3.28 Nepal; 3.29 New Caledonia; 3.30 New Zealand; 3.31 Niue; 3.32 Norfolk Island; 3.33 North Korea; 3.34 Palau; 3.35 Papua New Guinea; 3.36 Philippines; 3.37 Seychelles; 3.38 Singapore; 3.39 Solomon Islands; 3.40 South Korea; 3.41 Sri Lanka; 3.42 Taiwan; 3.43 Thailand; 3.44 The Northern Mariana Island; 3.45 Tokelau; 3.46 Tonga; 3.47 Tuvalu; 3.48 Vanuatu; 3.49 Vietnam; 3.50 Wallis and Futuna; 3.51 Western Samoa
4 EUROPE: 4.1 Executive Summary; 4.2 Albania; 4.3 Andorra; 4.4 Austria; 4.5 Belarus; 4.6 Belgium; 4.7 Bosnia and Herzegovina; 4.8 Bulgaria; 4.9 Croatia; 4.10 Cyprus; 4.11 Czech Republic; 4.12 Denmark; 4.13 Estonia; 4.14 Finland; 4.15 France; 4.16 Georgia; 4.17 Germany; 4.18 Greece; 4.19 Hungary; 4.20 Iceland; 4.21 Ireland; 4.22 Italy; 4.23 Kazakhstan; 4.24 Latvia; 4.25 Liechtenstein; 4.26 Lithuania; 4.27 Luxembourg; 4.28 Malta; 4.29 Moldova; 4.30 Monaco; 4.31 Norway; 4.32 Poland; 4.33 Portugal; 4.34 Romania; 4.35 Russia; 4.36 San Marino; 4.37 Slovakia; 4.38 Slovenia; 4.39 Spain; 4.40 Sweden; 4.41 Switzerland; 4.42 The Netherlands; 4.43 The United Kingdom; 4.44 Ukraine
5 THE AMERICAS & THE CARIBBEAN: 5.1 Executive Summary; 5.2 Antigua and Barbuda; 5.3 Argentina; 5.4 Aruba; 5.5 Barbados; 5.6 Belize; 5.7 Bermuda; 5.8 Bolivia; 5.9 Brazil; 5.10 Canada; 5.11 Chile; 5.12 Colombia; 5.13 Costa Rica; 5.14 Cuba; 5.15 Dominica; 5.16 Dominican Republic; 5.17 Ecuador; 5.18 El Salvador; 5.19 French Guiana; 5.20 Greenland; 5.21 Grenada; 5.22 Guadeloupe; 5.23 Guatemala; 5.24 Guyana; 5.25 Haiti; 5.26 Honduras; 5.27 Jamaica; 5.28 Martinique; 5.29 Mexico; 5.30 Nicaragua; 5.31 Panama; 5.32 Paraguay; 5.33 Peru; 5.34 Puerto Rico; 5.35 St. Kitts and Nevis; 5.36 St. Lucia; 5.37 St. Vincent and the Grenadines; 5.38 Suriname; 5.39 The Bahamas; 5.40 The British Virgin Islands; 5.41 The Cayman Islands; 5.42 The Falkland Islands; 5.43 The Netherlands Antilles; 5.44 The U.S. Virgin Islands; 5.45 The United States; 5.46 Trinidad and Tobago; 5.47 Uruguay; 5.48 Venezuela
6 THE MIDDLE EAST & AFRICA: 6.1 Executive Summary; 6.2 Afghanistan; 6.3 Algeria; 6.4 Angola; 6.5 Armenia; 6.6 Azerbaijan; 6.7 Bahrain; 6.8 Benin; 6.9 Botswana; 6.10 Burkina Faso; 6.11 Burundi; 6.12 Cameroon; 6.13 Cape Verde; 6.14 Central African Republic; 6.15 Chad; 6.16 Comoros; 6.17 Congo (formerly Zaire); 6.18 Cote d'Ivoire; 6.19 Djibouti; 6.20 Egypt; 6.21 Equatorial Guinea; 6.22 Ethiopia; 6.23 Gabon; 6.24 Ghana; 6.25 Guinea; 6.26 Guinea-Bissau; 6.27 Iran; 6.28 Iraq; 6.29 Israel; 6.30 Jordan; 6.31 Kenya; 6.32 Kuwait; 6.33 Kyrgyzstan; 6.34 Lebanon; 6.35 Lesotho; 6.36 Liberia; 6.37 Libya; 6.38 Madagascar; 6.39 Malawi; 6.40 Mali; 6.41 Mauritania; 6.42 Mauritius; 6.43 Morocco; 6.44 Mozambique; 6.45 Namibia; 6.46 Niger; 6.47 Nigeria; 6.48 Oman; 6.49 Pakistan; 6.50 Palestine; 6.51 Qatar; 6.52 Republic of Congo; 6.53 Reunion; 6.54 Rwanda; 6.55 Sao Tome E Principe; 6.56 Saudi Arabia; 6.57 Senegal; 6.58 Sierra Leone; 6.59 Somalia; 6.60 South Africa; 6.61 Sudan; 6.62 Swaziland; 6.63 Syrian Arab Republic; 6.64 Tajikistan; 6.65 Tanzania; 6.66 The Gambia; 6.67 The United Arab Emirates; 6.68 Togo; 6.69 Tunisia; 6.70 Turkey; 6.71 Turkmenistan; 6.72 Uganda; 6.73 Uzbekistan; 6.74 Western Sahara; 6.75 Yemen; 6.76 Zambia; 6.77 Zimbabwe
7 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS: 7.1 Disclaimers & Safe Harbor; 7.2 Icon Group International, Inc. User Agreement Provisions

More Global Antibody Technologies Reports

Global Protein Therapeutics Market Forecast to 2015 by RNCOS
Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most ...

Laboratory Chemical Reagents by Global Industry Analysts
This report analyzes the worldwide markets for Laboratory Chemical Reagents in US$ Million by the following Product Segments: Molecular Biology (Monoclonal & Polyclonal Antibodies, Gene ...

Antibody Drugs: Technologies and Global Markets by BCC Research
The global market for therapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic ...

The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies), 4th Edition by Kalorama Information
This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies) represents the fourth ...

The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others by BioSeeker Group AB
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely ...

See all reports like this >>

The 2010-2015 World Outlook for Monoclonal Antibody (MAb)-Based Products

Share this report

Other tasks

Research Assistance

Related Markets

Antibody Technologies Reports

Free Alert Me service